STAB1: A Potential Drug Target and Biomarker (G23166)

Target Name: STAB1

NCBI ID: G23166

STAB1

STAB1: A Potential Drug Target and Biomarker

STAB1 (Common lymphatic endothelial and vascular endothelial receptor-1) is a protein that is expressed in various tissues throughout the body, including the lymphatic system, blood vessels, and organs. It is a member of the immunoglobulin superfamily and is characterized by the presence of a constant and a variable region. The constant region of STAB1 is composed of a single amino acid residue, while the variable region consists of multiple amino acid residues.

The STAB1 protein is involved in the regulation of lymphatic homeostasis, which is critical for the proper functioning of the immune system. STAB1 is a potent negative regulator of the T-cell receptor (TCR), which is responsible for cell-mediated immunity. The regulation of TCR activity by STAB1 helps to ensure that T cells are properly controlled and do not cause excessive damage to other tissues.

In addition to its role in T-cell regulation, STAB1 is also involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. STAB1 has been shown to play a critical role in the regulation of angiogenesis by promoting the migration of endothelial cells to new blood vessels.

STAB1 is also involved in the regulation of inflammation and immune cell function. Its presence in various tissues suggests that it may be involved in the regulation of inflammation at the tissue level. Additionally, STAB1 has been shown to play a role in the regulation of immune cell function by promoting the growth and survival of immune cells.

Given its involvement in the regulation of lymphatic homeostasis, angiogenesis, and immune cell function, STAB1 is a potential drug target or biomarker. Studies have shown that blocking STAB1 with small interfering RNA (siRNA) has the potential to inhibit the growth of cancer cells and improve the efficacy of cancer treatments.

In addition to its potential as a drug target, STAB1 is also a potential biomarker for a variety of diseases. Its involvement in the regulation of lymphatic homeostasis and angiogenesis makes it a potential marker for diseases that affect these processes, such as cancer, autoimmune diseases, and vascular disease.

Given its potential as a drug target and biomarker, STAB1 is an attractive target for further research and development. Further studies are needed to fully understand its role in the regulation of lymphatic homeostasis and angiogenesis, as well as its potential as a drug target or biomarker.

Protein Name: Stabilin 1

Functions: Acts as a scavenger receptor for acetylated low density lipoprotein. Binds to both Gram-positive and Gram-negative bacteria and may play a role in defense against bacterial infection. When inhibited in endothelial tube formation assays, there is a marked decrease in cell-cell interactions, suggesting a role in angiogenesis. Involved in the delivery of newly synthesized CHID1/SI-CLP from the biosynthetic compartment to the endosomal/lysosomal system

The "STAB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STAB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets